LRRK2

News

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

R&D

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

Oncology

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Sales & Marketing

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.